Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse and limited cutaneous systemic scleroderma.

I Foeldvari1

  • 1University Children's Hospital, Pediatric Rheumatology Unit, Hamburg, Germany. foeld-vari@uke.uni-hamburg.de

Current Opinion in Rheumatology
|September 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.

Pediatric rheumatology online journal·2021
Same author

Temporomandibular joint involvement in patients with juvenile idiopathic arthritis: a retrospective chart review.

Scandinavian journal of rheumatology·2020
Same author

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Seminars in arthritis and rheumatism·2019
Same author

Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.

Scandinavian journal of rheumatology·2018
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Juvenile systemic scleroderma (jSSc) differs from adult disease, with unique pathogenic concepts and treatment considerations. New trials are emerging for this rare autoimmune condition, offering hope for better management.

Area of Science:

  • Rheumatology
  • Pediatric Autoimmune Diseases
  • Immunology

Background:

  • Juvenile systemic scleroderma (jSSc) is a rare autoimmune condition affecting children.
  • Limited large-scale data has historically hindered understanding of jSSc's distinct disease course compared to adult-onset scleroderma.
  • Pathogenetic concepts, including maternal cell persistence and graft-versus-host disease (GvHD) resemblance, warrant further investigation.

Purpose of the Study:

  • To characterize the disease course of juvenile systemic scleroderma (jSSc) based on the first comprehensive data collection.
  • To explore novel therapeutic avenues and treatment standards for pediatric patients with jSSc.
  • To inform the development of controlled clinical trials for jSSc.

Main Methods:

  • Analysis of a large dataset from a cohort of juvenile systemic scleroderma patients.

Related Experiment Videos

  • Review of existing literature on scleroderma pathogenesis and treatment.
  • Evaluation of current and emerging therapeutic options, including bone marrow transplantation.

    • Main Results:

    • The disease course in juvenile systemic scleroderma (jSSc) patients was found to differ significantly from that in adults.
    • Autologous bone marrow transplantation is a potential rescue therapy for select jSSc patients.
    • Palliative care strategies for jSSc have seen marked improvements.

    Conclusions:

    • Understanding the unique aspects of jSSc is crucial for developing effective treatment strategies.
    • Controlled trials are now being proposed for jSSc, marking a significant step forward in pediatric rheumatology.
    • Further research into the pathogenesis of jSSc is needed, particularly regarding maternal cell persistence.